Attain Commercial Success for your Chronic Inflammatory Skin Diseases Treatment Pipeline!

Therapeutic innovation in the dermatology space is growing at an exponential rate, propelling an increase in the awareness and knowledge of inflammatory skin conditions’ pathophysiology. 

In turn, a plethora of treatment options for chronic, moderate to severe dermatological diseases, and conditions of high unmet need, which concerns the lives of millions of individuals across the globe. As opportunities in this evolving landscape multiply, organisations and experts are motivated to pool their expertise to accelerate the delivery of innovative therapies to market. 

Following a successful launch in Europe in 2019, and a tremendous online experience in 2021, the 3rd Dermatology Drug Development Europe Summit, returned in April 2022, warmly welcoming everyone back to face-to-face gatherings.

We are the only end-to-end industry meeting committed to generating new dermatological therapeutics to market through collaboration. This summit delivered an unrivalled prospect to industry experts in the dermatology space. Exploring methods to tackle key challenges and reviewing opportunities in the development and delivery of pioneering dermatology medicines to market.


Health & Safety

The health, safety and well-being of our community remains our highest priority. Therefore, all attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours the event*.

For further information around Health and Safety onsite, please visit our FAQ here.

*Please note, this is subject to change at any time without prior notice.

From 2022's World-Class Speaker Faculty

Alan Irvine

MD DSc, Professor

Trinity College Dublin

Elena Rizova

Vice President, Head of Medical Affairs


Thorsten Thormann

Vice President, Head of Research & Early Development

LEO Pharma

Valerie Julia

Head of Research & Early Development


Many Thanks To Our Partners in 2022